Arctic Therapeutics is a clinical-stage biopharmaceutical company on a mission to treat and even prevent some of the world’s most pressing diseases by utilizing genetic sequencing to analyze and map the genetic causes of diseases at a granular level, applying our findings to develop effective treatments.



Our company was founded by Dr. Hakon Hakonarson in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), which he launched in 2006 and established it as the largest pediatric biobank and genomic database in the world. We maintain close research relationships with CAG and the Children’s Hospital of Philadelphia.



We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on diseases with high unmet need, ranging from rare and common forms of dementia to inflammatory skin disease and autoimmune disorders



Our approach is built on a strong foundation of internal discovery efforts, complemented by collaborations with academic institutions, industry partners, and business development initiatives to expand our pipeline. With patients at the center of everything we do, our goal is to accelerate the development of new treatments and bring them to market faster—delivering real impact for those in need.